Positive Airway Pressure Therapies for Heart Failure: What Do the Trials Tell Us?

URN to cite this document:: urn:nbn:de:bvb:355-epub-783378
DOI to cite this document:: 10.5283/epub.78337

Pec, Jan

; Arzt, Michael

License: Creative Commons Attribution Non-commercial 4.0
PDF - Published Version
(565kB)

Date of publication of this fulltext: 16 Dec 2025 12:05

Alternative links to fulltext:DOI Publisher

Details

Preview

Export bibliographical data

Abstract

Sleep-disordered breathing (SDB) represents a modifiable treatment target in patients with heart failure (HF). Despite the evolution of positive airway pressure (PAP) therapy over the past several decades, randomised controlled trials have not demonstrated a consistent benefit in reducing mortality or hospital admissions related to HF. As a result, the use of PAP therapy has been primarily ...